Navigation Links
Boston researchers share in $10 million grant to study HIV and alcohol
Date:9/26/2011

(Boston) Researchers from Boston University Schools of Medicine and Public Health (BUSM/BUSPH), Boston Medical Center (BMC), the University of California, San Francisco and the University of Pittsburgh, have joined together to examine the consequences of alcohol on HIV disease. The Uganda Russia Boston Alcohol Network for Alcohol Research Collaboration on HIV/AIDS (URBAN ARCH) will conduct and disseminate interdisciplinary alcohol/HIV research aimed at understanding the consequences of alcohol on HIV disease and advancing clinical approaches to mitigate its harm in the United States and globally. The National Institute on Alcohol Abuse and Alcoholism (NIAAA) is funding this five year consortium of multiple investigators.

To realize this goal, the URBAN ARCH Consortium will incorporate the expertise of researchers in epidemiology, internal medicine, addiction medicine, HIV/AIDS, psychiatry and biostatistics under the leadership of Consortium principal investigator Jeffrey Samet, MD, MA, MPH, professor of medicine at BUSM and chief of the section of internal medicine at BMC, a leader in the field of HIV and clinical addiction medicine.

The Consortium studies will build on three existing HIV-infected cohorts from Boston, Uganda, and Russia with distinctive strengths and well-characterized alcohol consumption patterns. The two international cohorts allow study of clinical issues that would not be possible in the United States, yet have important implications for US HIV-infected populations.

According to Samet, during the four decades of the HIV epidemic, many questions remain about how alcohol use affects HIV clinical manifestations and how approaches beyond antiretroviral treatments might mitigate alcohol-related harms. "Such questions about the complex relationship between HIV and alcohol need to be addressed in order to accelerate the development of more effective treatments," said Samet.

"By utilizing distinctive cohorts in the United States and abroad, the Consortium will be uniquely positioned to provide insights about the relationship of alcohol and HIV infection to improve clinical and public health outcomes for the associated consequences," he added.

Kendall Bryant, PhD, Scientific Collaborator from NIAAA stated that "this is one of six centers of excellence that will be able to address the optimal treatment of comorbidities impacted by alcohol among HIV-infected individuals and is consistent with the multidisciplinary approach laid out in the national AIDS strategic plan."

The other PI's on this project include: Debbie M. Cheng, ScD, BUSPH; Richard Saitz, MD, MPH, BMC/BUSM; Judith A. Hahn, PhD, University of California, San Francisco and Matthew Freiberg, MD, MSc, University of Pittsburgh.


'/>"/>

Contact: Gina DiGravio
gina.digravio@bmc.org
617-638-8480
Boston University Medical Center
Source:Eurekalert

Related medicine news :

1. CustomerCentric Selling and Kadient Announce Joint Event in Boston to Launch Strategic Partnership for Sales Enablement and Improvement
2. Tufts Medical Center and Boston Medical Center Nurses Hold a Joint Informational Picket to Protest Unsafe Staffing and Practice Conditions
3. Leading U.S. Infertility Practice Opens Boston IVF The Maine Center in Portland, Helping Build Families in Maine
4. Miles for Hope’s Moving Towards A Cure(SM) Brain Tumor Walk in Boston Raising Funds for Brain Tumor Vaccine and Massachusetts General Hospital
5. O'Lyn Roofing Contractors, Inc. Brings Professional and Eco-Friendly Roof Cleaning Services to Greater Boston MA Area Just in Time for Spring
6. Childrens Hospital Bostons Pain Treatment Service is named Clinical Center of Excellence
7. Boston researchers lead $15 million federal research grant to support advancement of health IT
8. NFL gives $1 million unrestricted gift to Boston University to study impact of brain injuries
9. Keeping the Boston Bruins Healthy. Their New - Very Cold - Secret Weapon Against Injuries
10. Save the date: American Chemical Society National Meeting in Boston, Aug. 22-26
11. Vietnamese Student Named UMass Boston JFK Award Winner
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... ... December 07, 2016 , ... ... medicine device WellnessPro Plus for consumers and healthcare professionals to manage chronic ... by expanding the treatment modalities available in a single device. The announcement ...
(Date:12/7/2016)... ... ... “Tomorrow Trump Goes To Washington”: a brief but engaging illustration depicting ... America. “Tomorrow Trump Goes To Washington” is the creation of published author, Nancy Engestrom, ... , Nancy attributes her patriotic nature to her WWII veteran father. She says, ...
(Date:12/7/2016)... ... (PRWEB) December 07, 2016 , ... Angioma Alliance ( http://www.angioma.org ... angiomas, was awarded a grant from the Julian Grace Foundation to increase its ... more people with cavernous angioma than anywhere in the world. Most share a ...
(Date:12/7/2016)... Mateo, CA (PRWEB) , ... December 07, 2016 , ... ... San Francisco Peninsula region, is proud to announce new city-specific pages as part of ... services for the elderly, they often look, first, for local agencies serving their city. ...
(Date:12/6/2016)... ... December 06, 2016 , ... ... collaborate in developing a vaccine against the Middle East Respiratory Syndrome Coronavirus (MERS-CoV). ... available in South Korea for emergency deployment in the event of a future ...
Breaking Medicine News(10 mins):
(Date:12/7/2016)... Dec. 7, 2016  Ionis Pharmaceuticals, Inc. (NASDAQ: IONS ... present a company overview at the BMO Capital Markets Prescriptions for ... York, NY . A live webcast of the ... the Ionis website.  The replay will be available within 48 hours ... ...
(Date:12/7/2016)... 7, 2016  Lannett Company, Inc. (NYSE: LCI ) ... Markets 2016 Prescription for Success Healthcare Conference on December 14, 2016 ... New York City . In addition, the ... Guggenheim Securities 4 th Annual Boston Healthcare Conference taking place ... ...
(Date:12/6/2016)...  Alopexx Oncology, LLC announced data from a Phase ... (immunocytokine) composed of interleukin-2 and a CD20-targeting monoclonal antibody. ... cells as Rituxan and maintains the activities of both ... in tumor targeting, engagement of the immune system, and ... the study (abstract #95954) were presented at the 58 ...
Breaking Medicine Technology: